Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Azilsartan Tablets Special Drug Use Surveillance: Long-term Use
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3437
- Registration Number
- NCT02092025
Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3304
- Registration Number
- NCT02089997
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3091
- Registration Number
- NCT02089737
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 116
- Registration Number
- NCT02085252
- Locations
- 🇫🇷
Ouzid, Paris La Défense,, Paris, France
🇫🇷Tenon Hospital Paris France, Paris, France
A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R
Phase 4
Completed
- Conditions
- Essential Hypertension Complicated by Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 33
- Registration Number
- NCT02079805
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT02079844
Phase III Study of Intramuscular TAK-816 in Healthy Infants
Phase 3
Completed
- Conditions
- Healthy VolunteersHaemophilus Influenzae Type b, Prevention
- Interventions
- Biological: TAK-816
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 31
- Registration Number
- NCT02074345
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
Phase 2
Completed
- Conditions
- Grade I or II Essential Hypertension
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 353
- Registration Number
- NCT02072330
Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3409
- Registration Number
- NCT02068495
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 374
- Registration Number
- NCT02068443
© Copyright 2025. All Rights Reserved by MedPath